Modeling of the impact of biological drugs in the economic burden of severe asthma
Bronchial asthma (BA) is worldwide lungs' illness, at least 1,5 mln people are on a dispensary in Russia. Non-control severe BA (SBA) can lead to increasing of direct Health Care System expenditures due to very oft en exacerbations (drugs costs, hospitalizations and out-patient cure etc.) as we...
Saved in:
Main Authors: | S. K. Zyryanov (Author), I. N. Dyakov (Author), O. I. Karpov (Author) |
---|---|
Format: | Book |
Published: |
Izdatelstvo OKI,
2020-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Influence of dupilumab on the economic burden of severe asthma and atopic dermatitis
by: I. S. Krysanov, et al.
Published: (2020) -
Social-economic burden of severe atopic dermatitis in the Russian Federation
by: I. S. Krysanov, et al.
Published: (2020) -
Economic expertise of alirocumab in standard lipid lowering therapy insusceptibility
by: S. K. Zyryanov, et al.
Published: (2018) -
Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation
by: S. K. Zyryanov, et al.
Published: (2020) -
The economic side of an oral sugar lowering therapy intensification by glucagon-like peptidt-1 receptor agonists
by: S. K. Zyryanov, et al.
Published: (2022)